All News
Utility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors
A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.
Read Article
The History of Citrullination
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read Article
The Danger Model as an Alternative Cause of Autoimmunity
The danger model was proposed by Matzinger as an alternative (or complement) to the traditional self-non-self (SNS) model of autoimmunity.
Read Article
Blau Syndrome - the Prototypic Autoinflammatory Granulomatous Disorder
The defining triad of Blau's syndrome includes granulomatous polyarthritis, dermatitis and uveitis. This rare, monogenic, autosomal dominant disorder stems from a "gain in function" mutation of the pattern recognition receptor NOD2.
Read Article
The Risk of Listeriosis in RA
In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.
Read Article
HLA-DRB1 Alleles Augment RA Severity and TNF Inhibitor Responses
The HLA-DRB1 haplotype is a known risk factor for RA.
Read Article
